Search results
Showing 526 to 540 of 997 results for death
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.
tests to identify whether they have a higher risk profile for early cardiac death, which could be reduced by revascularisation. This...
multidisciplinary orcomplex care needs, and recognising a person's preferred place of death in palliative care. In many locations around...
Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)
Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)
This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.
being more aware of the likely progression and prepare themselves for the death of their loved one.Accurate predictions of survival...
the person's place of residence, such as a nursing home, especially when death is imminent. Such discharges are often delayed because of...
coagulopathy could reduce mortality from haemorrhage, which is the main cause of death in patients with major trauma. Point-of-care...
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for people by ensuring that they get the most effective tests and treatments, and that they have access to suitable palliative care and follow-up.
Spesolimab for treating generalised pustular psoriasis flares (TA1070)
Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.
Evidence-based recommendations on idebenone (Raxone) for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over.
Show all sections
This document summarises the most common accessibility changes NICE is making in guidelines, and why
impact of anticipatory prescribing on outcomes such as preferred place of death and symptom control, and also uncertainty as to what...
individually and collectively, as predictors for physical harm (including death). Source guidance details Comes from guidance Eating...
Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)
Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making